Log In Get Started
Insider Trading May 22, 2026 09:01 AM

AtriCure Director's Sale Occurs Amid Strong Quarterly Results and Analyst Optimism

Analysis of recent insider activity contrasting with strong financial performance and revised analyst targets for ATRC.

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
ATRC

A director at AtriCure, Inc. recently sold a portion of company stock in a transaction that occurred while the stock was trading near $28.82. This sale takes place against a backdrop of positive developments, including the company reporting strong first-quarter 2026 financial results and receiving a Buy rating with an elevated price target from Needham.

AtriCure Director's Sale Occurs Amid Strong Quarterly Results and Analyst Optimism
ATRC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Director sale amid positive fundamentals: A director sold shares while the company reported strong Q1 2026 results and maintained guidance.
  • Analyst confidence remains high: Needham reiterated a Buy rating on AtriCure with a target price of $45.00 following impressive earnings data.
  • Operational growth in key segments: The first quarter saw revenue growth increase to 12.8% in constant currency, driven by Pain Management and Appendage Management.

Insider Activity at AtriCure (ATRC) Contrasts With Positive Operational Signals

Karen Prange, who serves as a director at AtriCure, Inc. (NASDAQ:ATRC), was involved in a recent transaction involving the sale of company shares. On May 20, 2026, Ms. Prange disposed of 3,000 shares of the firm's common stock. The total value realized from this disposition amounted to $85,950.

The selling shares were transacted at varied prices, ranging between $28.60 and $28.76 per share. This resulted in a weighted average sale price of $28.65 per share. Following the completion of this insider transaction, Ms. Prange's direct ownership stake in AtriCure common stock stands at 26,373 shares.

This recent director-level sale occurs as the broader market views AtriCure stock trading at $28.82, representing a decline of 27% year-to-date. Despite this downward trend relative to its annual performance, external analysis suggests underlying strength and potential undervaluation. According to InvestingPro's assessment, the stock is currently positioned as undervalued at existing price levels. Furthermore, the company has been assigned a

Risks

  • Year-to-date stock decline: ATRC shares are currently down 27% year-to-date.
  • Downward revision of EPS guidance: Although the company maintained revenue and adjusted EBITDA guidance for 2026, it did adjust its earnings per share guidance downward.
  • Profitability timeline: While analysts predict profitability this year with projected earnings of $0.13 per share, AtriCure was not profitable over the last twelve months.

More from Insider Trading

WhiteHorse Finance Director Bolduc Acquires Nearly $100K in Company Stock Jun 5, 2026 Delek US Holdings Director Offloads Shares Amid Strong Stock Performance Jun 5, 2026 Natera CEO Executes $9.09 Million Stock Sale Under Pre-Arranged Plan Jun 5, 2026 ACM Research Executive Executes Pre-Planned Stock Sales Amid Earnings Beat and Capital Raise Jun 5, 2026 Sitime Executive Fariborz Assaderaghi Disposes of $1.41M in Shares Amid Volatile Market Conditions Jun 5, 2026